Please assess the completion status of the following clinical trial:

Trial Title: Magnesium Supplementation in Diabetic Nephropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥ 18 years.~2. Type I or II diabetic patientCKD stage 3 ( eGFR = 30 - 59 ml/min) or stage 4 ( eGFR 15-29 ml/min)~3. Proteinuria 30-300 mg/dl (microalbuminuria)~4. Low SMg levels (1.4-1.9 mg/dL; 0.58-0.78 mM) to normal (1.7-2.4 mg/dL; 0.7 -1.1 mmol/L; 1.4-2.0 mEq/L).~5. Life expectancy \>12 months.~6. Women of child-bearing age should be using contraceptives as Hormonal contraceptive or Intra-uterine device.~Exclusion Criteria:~1. Kidney donor recipient.~2. Current treatment with Mg supplements.~3. Any condition impairing intestinal absorption of Mg (e.g: chronic pancreatitis, short bowel syndrome)~4. Active malignancy.~5. Pregnancy or breastfeeding.~6. Cardiac Arrythmias.~7. Allergy towards the Mg supplement.~8. Participation in other interventional trials.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Magnesium arm (Type: EXPERIMENTAL): 30 patients will receive the standard therapy (anti-diabetic ) + magnesium supplement
- Control (Type: ACTIVE_COMPARATOR): 30 patients will receive the standard therapy (anti-diabetic)

Based on this trial design, predict the completion outcome and termination type (if applicable).